NEW YORK — Aspira Women's Health said on Wednesday that it has formed a comarketing and distribution alliance for its Ova1Plus ovarian cancer test with Opko Health subsidiary BioReference Laboratories.
Ova1Plus is designed to detect the risk of ovarian malignancy in women with adnexal masses prior to surgery. It combines two US Food and Drug Administration-approved blood tests: Ova1 and OVERA, which analyze levels of five biomarkers to provide a malignancy risk index.
Under the terms of the deal, Aspira and Elmwood Park, New Jersey-based BioReference will collaborate to sell Ova1Plus to gynecologists and other women's healthcare providers across the US. Financial and other terms were not disclosed.
"The agreement has been structured to support rapid volume growth," Greg Richard, head of strategy and business development at Aspira, said in a statement. "Sales professionals from each company will work collaboratively to ensure physicians understand the power of our ovarian cancer risk assessment products to expand market access and provider adoption."
In August, Austin, Texas-based Aspira reported a 17 percent rise in second quarter sales of Ova1Plus to $2.0 million.